In carcinoma of unknown primary, if the tissue marker CDX-2 is positive, it indicates:
First, CDX-2 is a transcription factor. I remember it's associated with intestinal differentiation. So, if a tumor tests positive for CDX-2, it's likely of gastrointestinal origin. Carcinomas with CDX-2 positivity are often from the GI tract, like the stomach, colon, or appendix. Maybe the question is asking which primary site this indicates.
The options aren't listed, but the user wants me to explain each wrong option as well. Let me think of possible distractors. Common primaries in CUP include lung, breast, prostate, GI, etc. So possible options could be lung, breast, prostate, or GI tract. If CDX-2 is positive, the correct answer would be GI tract.
Why is CDX-2 specific for GI? Because it's expressed in normal intestinal epithelium and tumors arising from there. Other markers like TTF-1 are for lung or thyroid, PSA for prostate. So if the options include, say, lung (TTF-1), breast (ER/PR), prostate (PSA), then GI would be correct.
For the clinical pearl, CDX-2 is a key marker for GI primaries in CUP. Students should remember that CDX-2 is a GI marker, while others are for different sites. Mnemonic: CDX stands for "Carcinoembryonic Antigen in Digestive eXtract"? Not sure, but maybe "CDX" as in "Digestive" helps.
Now, structuring the explanation. The core concept is the role of CDX-2 in tumor origin. Then, explaining why GI is correct, and other options incorrect. Each wrong option's reasoning. Then the clinical pearl about CDX-2 being a GI marker.
I need to make sure the explanation is concise, under 2500 characters. Use bold for key terms, avoid markdown except for the specified sections. Check for medical accuracy—CDX-2 is indeed a marker for GI tumors. Confirm that other markers are not associated with CDX-2. For example, TTF-1 for thyroid/lung, PAX8 for kidney/ovary, etc. So if the options included those, they'd be wrong.
Finalizing the answer: Correct answer is GI tract. The explanation should cover that CDX-2 is a GI marker, other options are other primaries with different markers, and the clinical pearl to remember CDX-2 for GI.
**Core Concept**
CDX-2 is a homeobox transcription factor specifically expressed in gastrointestinal (GI) epithelium. Its positivity in metastatic carcinomas helps identify GI tract primaries in cancers of unknown origin, particularly adenocarcinomas.
**Why the Correct Answer is Right**
CDX-2 is a sensitive and specific marker for GI-derived tumors, including those from the stomach, small intestine, colon, and appendix. It is not expressed in non-GI tissues, making it critical for differentiating GI primaries from other metastatic cancers (e.g., lung, breast). Positive staining confirms an origin in the GI tract, guiding further diagnostic workup and treatment.
**Why Each Wrong Option is Incorrect**
**Option A:** Lung primaries